Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: Temporal trends and evidence for vaccine-driven evolution

Infection and Immunity

Volumn 66, Issue 2, 1998, Pages 670-675

  Mooi, Frits R ^a   Van Oirschot, Hans ^a   Heuvelman, Kees ^a   Van der Heide, Han G J ^a   Gaastra, Wim ^b   Willems, Rob J L ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; PERTUSSIS VACCINE;

ACTIVE IMMUNIZATION; AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL MUTATION; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; DNA POLYMORPHISM; DRUG EFFICACY; IMMUNOGENICITY; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; STRAIN DIFFERENCE; T LYMPHOCYTE ACTIVATION;

EID: 0031908224     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.2.670-675.1998     Document Type: Article

References (35)

1. Andrews, R., A. Herceq, and C. Roberts. 1997. Pertussis notifications in Australia. Commun. Dis. Intell. 21:145-148.
2. Arico, B., R. Gross, J. Smida, and R. Rappuoli. 1987. Evolutionary relationships in the genus Bordetella. Mol. Microbiol. 1:301-308.
3. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 1989. Current protocols in molecular biology, p. 2.4.1-2.4.2. Green Publishing Associates, Brooklyn, N.Y.
4. Bass, J. W., and S. R. Stephenson. 1987. The return of pertussis. Pediatr. Infect. Dis. J. 6:141-144.
5. Bass, J. W., and R. R. Wittier. 1994. Return of epidemic pertussis in the United States. Pediatr. Infect. Dis. J. 13:343-345.
6. Capiau, C., S. A. Carr, M. E. Hemling, et al. 1990. Purification, characterization and immunological evaluation of the 69-kDa outer membrane protein of Bordetella pertussis, p. 75-85. In C. R. Manclark (ed.). Proceedings of the Sixth International Symposium on Pertussis. Publication no. (PDA) 90-1164. Department of Health and Human Services. Bethesda, Md.
7. Charles, I., N. Fairweather, D. Pickard, J. Beesley, R. Anderson, G. Dougan, and M. Roberts. 1994. Expression of the Bordetella pertussis P.69 pertactin adhesin in Escherichia coli: fate of the carboxy-terminal domain. Microbiology 140:3301-3308.
8. Charles, I. G., G. Dougan, D. Pickard, S. Chatfield, M. Smith, P. Novotny, P. Morrissey, and N. F, Fairweather. 1989. Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis. Proc. Natl. Acad. Sci. USA 86:3554-3558.
9. Charles, I. G., J. L. Li, M. Roberts, K. Beesley, et al. 1991. Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussis. Eur. J. Immunol. 21:1147-1153.
10. Cherry, J. D. 1996. Historical review of pertussis and the classical vaccine. J. Infect. Dis. 174(Suppl. 3):S259-S263.
11. deMelker, H. E., M. A. E. Conyn-van Spaendock, H. C. Rümke, J. K. van Wijngaarden, F. R. Mooi, and J. F. P. Schellekens. 1997. Pertussis in the Netherlands: an outbreak despite high levels of immunization with whole cell vaccine. Emerg. Infect. Dis. 3:175-178.
12. DeSerres, G., N. Boulianne, M. Douville-Fradet, and B. Duval. 1995. Pertussis in Quebec: ongoing epidemic since the late 1980s. Can. Commun. Dis. Rep. 15:45-48.
13. Emsley, P., I. G. Charles, N. F. Fairweather, and N. W. Isaacs. 1966. Structure of Bordetella pertussis virulence factor P.69 pertactin. Nature 381:90-92.
14. Greco, D., S. Salmaso, and P. Mastrantonio. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:341-348.
15. Khelef, N., B. Dame, M. J. Quentin-Millet, and N. Guiso. 1993. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species. Infect. Immun. 61:486-490.
16. Kobisch, M., and P. Novotny. 1990. Identification of a 68-kilodahon outer membrane protein as the major protective antigen of Bordetella bronchiseptica by using specific-pathogen-free piglets. Infect. Immun. 58:352-357.
17. Leininger, E., C. A. Ewanowich, A. Bhargava, M. S. Peppier, J. G. Kenimer, and M. J. Brennan. 1992. Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and filamentous hemagglutinin. Infect. Immun. 60:2380-2385.
18. Levin, B. R. 1988. Frequency-dependent selection in bacterial populations. Philos. Trans. R. Soc. Lond. Ser. B 319:459-472.
19. Li, L. J., N. F. Fairweather, P. Novotny, G. Dougan, and I. G. Charles. 1992. Cloning, nucleotide sequence and heterologous expression of the protective outer-membrane protein P.68 pertactin from Bordetella bronchiseptica. J. Gen. Microbiol. 138:1697-1705.
20. Locht, C., and J. M. Keith. 1986. Pertussis toxin gene: nucleotide sequence and genetic organization. Science 232:1258-1264.
21. Loosmore, S., J. Cunningham, W. Bradley, F. Yao, G. Dekaban, and M. Klein. 1989. A unique sequence of the Bordetella pertussis toxin operon. Nucleic Acids Res. 17:8365.
22. Madoff, L. C., J. L. Michel, E. W. Gong, D. E. Kling, and D. L. Kasper. 1996. Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc. Natl. Acad. Sci. USA 93:4131-4136.
23. Nennig, M. E., H. R. Shinefield, K. M. Edwards, S. B. Black, and B. H. Fireman. 1996. Prevalence and incidence of adult pertussis in an urban population. JAMA 275:1672-1674.
24. Nicosia, A., M. Perugini, C. Franqini, et al. 1986. Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. Proc. Natl. Acad. Sci. USA 83:4631-4635.
25. Ochman, H., and A. C. Wilson. 1987. Evolution in bacteria: evidence for a universal substitution rate in cellular genomes. J. Mol. Evol. 26:74-86.
26. Peppoloni, S., M. Pizza, M. T. De Magistris, A. Bartoloni, and R. Rappuoli. 1995. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin. Physiol. Chem. Phys. Med. NMR 27:355-361.
27. Roberts, M., J. Tite, N. Fairweather, G. Dougan, and I. Charles. 1992. Recombinant P69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection. Vaccine 10:43-52.
28. Robertson, B. D., and T. F. Meyer. 1992. Genetic variation in pathogenic bacteria. Trends Genet. 8:422-427.
29. SAS Institute Inc. 1989. SAS/STAT user's guide, version 6, 4th ed., vol. 2. SAS Institute Inc., Gary, N.C.
30. Schmitt, H. J., C. H. W. Vonkonig, and A. Neiss. 1996. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 275:37-41.
31. Trollfors, B., J. Taranger, T. Lagergard, L. Lind, V. Sundh, G. Zackrisson, C. U. Lowe, W. Blackwelder, and J. B. Robbins. 1995. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333:1045-1050.
32. Ui, M. 1988. The multiple biological activities of pertussis toxin, p. 39-74. In A. C. Wardlaw and R. Parton (ed.), Pathogenesis and immunity in pertussis. John Wiley & Sons, New York, N.Y.
33. Verwey, W. F., E. H. Thiele, D. N. Sage, and L. T. Suchardt. 1949. A simple liquid culture medium for the growth of Haemophilus pertussis, J. Bacteriol. 58:127-134.
34. VanderZee, A., S. Vernooij, M. Peeters, J. D. A. VanEmbden, and F. R. Mooi. 1996. Dynamics of the population structure of Bordetella pertussis as measured by IS1002-associated RFLP: comparison of pre- and postvaccination strains and global distribution. Microbiology 42:3479-3485.
35. Willems, R. J. L., and F. R. Mooi. 1996. From whole cell to acellular vaccines. Rev. Med. Microbiol. 7:13-21.